Takara Bio (FRA:TF2) ROE % Adjusted to Book Value: 0.06% (As of Mar. 2026)


FRA:TF2 Takara Bio Inc FRA:TF2
74 GF Score
Price €5.95
GF Value €4.46
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Takara Bio ROE % Adjusted to Book Value?

Takara Bio FRA:TF2 74 ROE % Adjusted to Book Value is 0.06% as of Mar. 2026. GuruFocus rates FRA:TF2 with a GF Score™ of 74/100 and a GF Value™ of €4.46 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Takara Bio's ROE % for the quarter that ended in Mar. 2026 was 0.08%. Takara Bio's PB Ratio for the quarter that ended in Mar. 2026 was 1.29. Takara Bio's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was 0.06%.

Takara Bio ROE % Adjusted to Book Value Related Terms

Takara Bio ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Takara Bio's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Takara Bio ROE % Adjusted to Book Value Chart

Takara Bio Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.74 8.19 1.25 1.15 -6.33

Takara Bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.79 -6.45 -19.42 -11.93 0.06

FRA:TF2 vs VRTX, REGN, ALNY: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Takara Bio's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Takara Bio ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Takara Bio's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Takara Bio's ROE % Adjusted to Book Value falls into.


FRA:TF2
74GF Score
Takara Bio Inc FRA:TF2
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Takara Bio ROE % Adjusted to Book Value Calculation

Takara Bio's ROE % Adjusted to Book Value for the fiscal year that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-8.16% / 1.29
=-6.33%

Takara Bio's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.08% / 1.29
=0.06%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of 0.06% mean?
Takara Bio (FRA:TF2) has a ROE % Adjusted to Book Value of 0.06% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Takara Bio and its competitors.
Is Takara Bio's ROE % Adjusted to Book Value too high?
Takara Bio's current ROE % Adjusted to Book Value is 0.06%. Overall, Takara Bio has a GF Score™ of 74/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Takara Bio's ROE % Adjusted to Book Value compare to VRTX and REGN?
Takara Bio's ROE % Adjusted to Book Value of 0.06% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Takara Bio and its competitors. Takara Bio's current ROE % Adjusted to Book Value is 0.06%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Takara Bio stock overvalued right now?
Based on GuruFocus' analysis, Takara Bio (FRA:TF2) is currently considered Significantly Overvalued. The stock's GF Value™ is €4.46, compared to a current price of €5.95 — trading 33.4% above its estimated fair value. The current ROE % Adjusted to Book Value is 0.06%. Takara Bio's overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Takara Bio (FRA:TF2), the current ROE % Adjusted to Book Value is 0.06% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Takara Bio (FRA:TF2) Overvalued in 2026?

Based on GuruFocus' analysis, Takara Bio stock appears to be overvalued. The current stock price of €5.95 is trading 33.4% above its estimated GF Value™ of €4.46. GuruFocus considers Takara Bio to be Significantly Overvalued.

Key valuation signals for FRA:TF2:

  • ROE % Adjusted to Book Value: 0.06%
  • GF Value™: €4.46 vs. price of €5.95 (33.4% above fair value)
  • GF Score™: 74/100 with 6 warning signs

No single metric tells the full story. See the FRA:TF2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Takara Bio Business Description

Other Exchanges 4974:Japan
Address Nojihigashi 7-4-38 Kusatu, Shiga, Otsu, JPN, 520-0058
Takara Bio Inc is a biotechnology company that develops gene therapy procedures. The company reports in three business segments: Bioindustry, Gene therapy, and AgriBio. Takara's bioindustry business provides research reagents, scientific instruments, and various contracted services to universities and companies around the world. The company's gene therapy business is focused on treating cancer and HIV. Its AgriBio business aims to leverage biotechnologies in the food ingredient field, including large-scale mushroom production. The vast majority of Takara's revenue is derived from its bioindustry segment.
74GF Score

Get the complete analysis for FRA:TF2

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.95
Price
€4.46
GF Value